Spectral Medical (TSE:EDT) Posts Quarterly Earnings Results

Spectral Medical (TSE:EDT) issued its quarterly earnings results on Friday. The company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of C$0.28 million during the quarter.

Spectral Medical Trading Down 2.0%

TSE:EDT traded down C$0.02 on Friday, hitting C$0.97. 5,110 shares of the stock were exchanged, compared to its average volume of 52,880. The stock has a market capitalization of C$284.75 million, a price-to-earnings ratio of -8.08 and a beta of 0.86. Spectral Medical has a 52 week low of C$0.86 and a 52 week high of C$1.54. The company has a debt-to-equity ratio of 26.03, a quick ratio of 0.45 and a current ratio of 0.61. The company’s 50-day moving average price is C$1.14 and its 200 day moving average price is C$1.31.

Spectral Medical Company Profile

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.